Prostate-specific antigen (PSA), considered only an established marker for the detection of prostate cancer, has been identified as a member (hK3) of the human kallikrein family of serine proteases and now, it is known that PSA is not specific to prostate, semen, and gender. Increased PSA serum levels have been reported also in cardiovascular patients and both elevated as well as diminished PSA have been reported during acute myocardial infarction (AMI). Preliminary observations have concluded that when elevation of prostate-specific antigen occurs during AMI, it seems to relate to a higher occurrence of major adverse cardiac events and that coronary lesions are frequent and often more severe than when a diminution of PSA occurs. Large studies need to be done to confirm these preliminary results but the journey of PSA could be longer than expected.
Prostate-specific antigen (PSA) has been identified as a member (hK3) of the human kallikrein family of serine proteases, 1,2 and it has been considered only an established marker for the detection of prostate cancer. 3 Such sources including other malignant and non-malignant non-prostatic diseases 4 -11 are also known to be associated with increased PSA serum levels and now, it is known that PSA is not specific to prostate, semen, and gender. Prostatespecific antigen kallikrein does not seem to have kinin-generating activity. 12 The inactive precursor form of PSA, proPSA, is converted rapidly to active PSA by human kallikrein 2, 13 which has also bradykinin-generating activity. 14, 15 Human kallikrein 2 also activates the single-chain urokinase-type plasminogen activator 16 and forms a complex with plasminogen activator inhibitor-1 too.
17
Other proteases also seem to be involved in the formation of active PSA. 13 It has been suggested that PSA may be an inducer of apoptosis, a negative regulator of growth, 18 an inhibitor of angiogenesis. 19, 20 Prostate-specific antigen may also cleave insulin-like growth factor binding protein-3, thus liberating insulin-like growth factor I, 21 -23 a mitogen independently associated with increased all-cause mortality 24 and risk of development of CHF, 25 although it has been reported that it invades the scarred myocardium and generates myocytes and coronary vessels improving the haemodynamics of the infarcted heart. 26 Furthermore, PSA may activate latent transforming growth factor-b, 27 a key cytokine that both initiates and terminates tissue repair, and its sustained production underlies the development of tissue fibrosis, 28, 29 particularly after MI. Notably, PSA levels have been reported declined by a statistically significant extent after initiation of statin treatment 30 and regulation of PSA expression has been also reported by an angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. 31 Increased PSA serum levels have been reported also in cardiovascular patients. 6,8,32 -38 Prolonged cardiopulmonary resuscitation, 8, 32 cardiac surgery and extracorporeal cardiopulmonary bypass, 6 cardiogenic shock due to acute myocardial infarction (AMI) 33 are also frequently associated with increases of PSA and it has been interpreted as marker of prostatic ischaemia. 6 Both elevated 3,34 -38 and diminished PSA 39 have been reported during AMI and our preliminary observations 38, 39 have concluded that when the elevation of PSA occurs during AMI, coronary lesions are frequent and often more severe than when a diminution of PSA occurs. Moreover, our preliminary observations have concluded also that when the elevation of PSA occurs during AMI, it seems to relate to a higher occurrence of major adverse cardiac events in the first 8 days after AMI than when a diminution of PSA occurs. 40 Large studies need to be done to confirm these preliminary results and to clear apparently conflicting observations. The journey of PSA could be longer than expected.
